IGM Biosciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
IGM Biosciences announced its participation at the 2021 Cantor Virtual Global Healthcare Conference scheduled for September 29, 2021, at 3:20 p.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IGM Biosciences announced its participation at the 2021 Cantor Virtual Global Healthcare Conference scheduled for September 29, 2021, at 3:20 p.m. EDT. The live presentation will be accessible via a webcast on the company’s website, specifically in the Investors section. IGM Biosciences is focused on developing engineered IgM antibodies and has created a proprietary platform since its establishment. A replay of the event will be available for 90 days post-presentation.
Details
News Market Reaction – IGMS
The recorded move for IGMS in the trading session of this news was -3.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021 at 3:20 p.m. EDT.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Contact
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.